Optimizing Treatment forHER2-Positive Advanced Breast

Cancer

Program Goals

CLEOPATRA Study Design

First-Line Therapy of HER2+ MBC

Therapy of MBC After Progression on First-Line Anti-

HER2 Treatment

EMILIA: PFS

EMILIA: OS at Second Interim Analysis

EMILIA: Hematologic Adverse Events

First-Line Treatment With T-DM1 vs Trastuzumab +

Docetaxel

BOLERO-3: Previous Therapy